Outpacing
cancer starts with early detection

Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.

Outpacing
cancer starts with early detection

Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.

Outpacing cancer starts with early detection
Two Freenome clinicians working in a lab where outpacing cancer starts with early detection

A novel approach to screening

Freenome’s intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages.

Powered by a rigorous clinical program

Our research programs drive discovery, development, and validation of our early cancer detection tests.

A doctor having a discussion with a patient

Multi-disciplinary leadership with purpose

We bring together passionate creators and ambitious builders. Together, we are relentless in pushing for what’s possible in early cancer detection.

Riley Ennis, Co-Founder and Chief Product Officer

“It was clear that to make a real dent in ending cancer, we needed to improve the entire concept of early detection. That was the motivation to start Freenome.”

Riley Ennis, Co-Founder and Chief Product Officer

Riley Ennis
Co-founder and Chief Product Officer